Synthesis and application of pH activated photosensitizer

By adding a pH-activated photosensitizer of thiophene structure synthesized on rhodamine derivatives, the problem of poor side effects and imaging effects of photodynamic therapy in tumor treatment is solved, and efficient fluorescence imaging of NIR-II region is achieved and Tumor cell killing provides a new integrated cancer diagnosis and treatment strategy.

CN118908965AActive Publication Date: 2024-11-08HUANGHUAI UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410965757.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08
Estimated Expiration
2044-07-18

AI Technical Summary

Technical Problem

Existing photodynamic therapy has problems with side effects on normal tissues and poor imaging effects when treating tumors, especially in the complex tumor microenvironment, the therapeutic effect and imaging effects of single photodynamic therapy are insufficient.

Method used

Using rhodamine derivatives as raw materials, a pH-activated photosensitizer without heavy metals is synthesized by adding thiophene structure to its structure. This photosensitizer is activated in the presence of a specific biomarker and can be in the near infrared second zone ( NIR-II) generates fluorescence signals and reactive oxygen species for precise killing of tumor cells and performing in vivo imaging.

Benefits of technology

It realizes efficient fluorescence imaging and tumor cell killing in the NIR-II area, reduces damage to normal tissues, provides a new integrated diagnosis and treatment strategy, enhances the diagnosis and treatment effect of photodynamic therapy, and provides new ideas for cancer treatment .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908965A_ABST
    Figure CN118908965A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological detection and biological medicine, and particularly relates to synthesis and application of a pH activated photosensitizer. In order to construct an NIR-II activated photosensitizer, a pH activated photosensitizer is synthesized by modifying a rhodamine derivative serving as a raw material, and the NIR-II activated photosensitizer does not have fluorescence emission capability and can be activated by illumination after H < + > stimulation, so that a large amount of active oxygen and fluorescence emission are generated. Wherein the generated active oxygen can destroy proteins, DNA and lipids in cells to cause cell apoptosis, so that tumor cells are killed; the fluorescence emission can generate a strong fluorescence signal in an NIR-II region, and NIR-II in-vivo imaging can be carried out on a cancerous part. Therefore, the pH activated photosensitizer provided by the invention can provide a new thought for the design of the activated photosensitizer, and has important reference significance for realizing diagnosis and treatment integration and overcoming cancer problems.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biological detection and biomedicine, and specifically relates to the synthesis and application of a pH-activated photosensitizer. Background Art

[0002] With the continuous improvement of the quality of life, health issues are receiving more and more attention from people. In recent years, the cancer problem has become a focal issue in medical and health care and has attracted much attention. The commonly used methods for treating cancer are radiotherapy, chemotherapy and surgical resection. However, these treatment methods have more or less defects, making the treatment results unsatisfactory. Photodynamic therapy (PDT) is a non-invasive diagnosis and treatment method. Due to its many advantages such as small surgical trauma, excellent selectivity, few side effects, ability to coordinate surgical treatment, and ability to eliminate hidden lesions, it is widely used in cancer treatment and has attracted much attention from scholars.

[0003] PDT is a new disease treatment method based on the interaction between light, photosensitizer and oxygen. Photosensitizer is one of the key elements of PDT treatment. It is a photoactive substance that can absorb light energy of a specific wavelength and convert it into chemical energy, thereby triggering a series of chemical reactions. Among them, activated photosensitizers can only produce fluorescence effects and reactive oxygen under the stimulation of specific biomarkers in tumor cells. By selectively activating photosensitizers to control the production of reactive oxygen in tumor cells, tumor cells can be directly killed and toxic side effects on normal tissues can be reduced, so that tumor cells can be detected more accurately and treated more precisely. Therefore, photosensitizers that can be specifically activated by biomarkers in tumors have received widespread attention.

[0004] The wavelength of near-infrared light is between visible light and mid-infrared light, with a wavelength of 700 to 2500 nm. Near-infrared light is subdivided into different optical windows according to its wavelength. For example, the wavelength of the first near-infrared (NIR-Ⅰ) region, which was studied earlier, is in the range of 700 to 900 nm, and the wavelength of the second near-infrared (NIR-Ⅱ) region, which has been studied more in recent years, is in the range of 900 to 1700 nm. Compared with visible light and near-infrared region 1 imaging, near-infrared region 2 imaging has many advantages, such as less adverse reactions, faster imaging speed, and low autobioluminescent background. Since light has the characteristic that the scattering intensity decreases exponentially with the increase of wavelength, near-infrared region 2 imaging has better tissue penetration and spatial resolution than visible light and near-infrared region 1 imaging. Due to the complexity of the tumor microenvironment, the auxiliary effect of single photodynamic therapy on tumor elimination and immunotherapy is usually weakened. Therefore, if the advantages of NIR-Ⅱ imaging and activated photosensitizers can be combined to develop NIR-Ⅱ activated photosensitizers, it is expected to further enhance the diagnostic and therapeutic effects of photodynamic therapy.

[0005] In addition, since tumor tissue is more acidic than normal tissue, it can be used as a target for pH-activated photosensitizers. + As a biomarker in cancer cells to activate photosensitizers, it will surely have broad application prospects. Summary of the invention

[0006] In order to overcome the above-mentioned deficiencies of the prior art, the present invention uses rhodamine derivatives as raw materials to construct a pH-activated photosensitizer, which is an integrated diagnosis and treatment dosage form and can provide a new strategy for the integration of diagnosis and treatment in cancer treatment, and has broad development prospects.

[0007] In order to achieve the above object, the technical solution adopted by the present invention is:

[0008] The first aspect of the present invention provides a pH-activated photosensitizer, the structural formula of the pH-activated photosensitizer is as follows:

[0009]

[0010] The second aspect of the present invention provides a method for preparing the pH-activated photosensitizer according to the first aspect. According to the following reaction formula, the preparation method comprises the following steps:

[0011]

[0012] S1, dissolving compound 2b in acetic acid, adding 2,2':5',2"-terthiophene-5-carboxaldehyde, and then reflux at 100°C-120°C for 8-15 hours. After the reaction, cooling under reduced pressure, concentrating, and purifying by column chromatography to obtain compound 2b+3t;

[0013] S2. Dissolve compound 2b+3t in dichloromethane, add NHS and EDC, reflux with stirring at 35°C-50°C for 4-7 hours, then add adamantine and triethylamine, continue to reflux with stirring at 35°C-50°C for 8-15 hours, and after the reaction, concentrate under reduced pressure and purify by column chromatography to obtain a pH-activated photosensitizer.

[0014] Only produced when specific biomarkers are present 1O2-activated photosensitizers can minimize damage to normal tissues. Among them, photosensitizers that do not contain heavy metal atoms have the advantages of low toxicity, long triplet lifetime, good photostability, and low cost. When the fluorescence emission range of the photosensitizer is in the near-infrared second region (NIR-Ⅱ) (900-1700nm), it can be used for in vivo biological imaging. Compared with visible light and near-infrared first region imaging, near-infrared second region imaging has many advantages such as small adverse reactions, fast imaging speed, deep tissue penetration, high image contrast, and low auto-bioluminescent background. The present invention synthesizes a photosensitizer that does not contain heavy metal atoms by modifying rhodamine derivatives and adding a thiophene structure to its structure. Through experimental detection of the hair type, the synthesized photosensitizer showed a good singlet oxygen production ability. On this basis, the photosensitizer was further modified to obtain a pH-activated photosensitizer. By monitoring the changes in the fluorescence emission spectrum of this activated photosensitizer, it was found that this activated photosensitizer has good fluorescence emission ability in the NIR-Ⅱ region. The above research results provide new ideas for the integrated diagnosis and treatment of cancer.

[0015] Preferably, in S1, the molar ratio of the compound 2b to 2,2':5',2"-terthiophene-5-carboxaldehyde is 0.8-1.0:2.0-3.0.

[0016] Preferably, the column chromatography purification in S1 uses dichloromethane:methanol=200:1-100; v / v (more preferably 11 v / v) as the elution solvent.

[0017] Preferably, in S2, the molar ratio of the compound 2b+3t, NHS, EDC and adamantine is 0.06-0.09: 0.1-0.2: 0.06-0.09: 0.2-0.3.

[0018] Preferably, in S2, the concentration of the compound 2b+3t in dichloromethane is 40-60 mg / 20 mL.

[0019] Preferably, in S2, NHS and EDC are added under light-protected conditions.

[0020] Preferably, the column chromatography purification in S2 uses dichloromethane:ethanol=100:1-100:v / v (more preferably 5v / v) as the elution solvent.

[0021] The third aspect of the present invention provides the use of the pH-activated photosensitizer described in the second aspect in the preparation of an integrated tumor diagnosis and treatment preparation.

[0022] The activated photosensitizer synthesized by the method of the present invention is +After stimulation, a large amount of reactive oxygen and fluorescence emission can be generated through light exposure, thereby killing tumor cells. It can also produce a strong fluorescence signal in the NIR-Ⅱ region and perform NIR-Ⅱ in vivo imaging of the cancerous site. It is an integrated dosage form for tumor diagnosis and treatment with broad application prospects.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] The present invention uses rhodamine derivatives as raw materials to construct a pH-activated photosensitizer. This NIR-Ⅱ region activated photosensitizer itself does not have the ability to emit fluorescence and needs to be exposed to H + It can only be activated by light after stimulation, thereby generating a large amount of reactive oxygen and fluorescence emission. Among them, the reactive oxygen generated will destroy the proteins, DNA, and lipids in the cells, leading to cell apoptosis, thereby killing tumor cells; the fluorescence emission can produce a strong fluorescence signal in the NIR-Ⅱ region, and can perform NIR-Ⅱ in vivo imaging of the cancerous site. It can be seen that the pH-activated photosensitizer of the present invention is an integrated diagnosis and treatment dosage form, which can provide new ideas for the design of activated photosensitizers, and has important reference significance for realizing integrated diagnosis and treatment and overcoming cancer problems. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 2b+t 1 H NMR spectrum.

[0026] Figure 2 2b+2t 1 H NMR spectra.

[0027] Figure 3 2b+3t 1 H NMR spectra.

[0028] Figure 4 2b+t 13 C NMR spectrum.

[0029] Figure 5 2b+2t 13 C NMR spectrum.

[0030] Figure 6 2b+3t 13 C NMR spectrum.

[0031] Figure 7 This is the HRMS chart of 2b+t.

[0032] Figure 8 This is the HRMS diagram of 2b+2t.

[0033] Fig. 9 This is the HRMS diagram of 2b+3t.

[0034] Fig.10 The UV absorption spectrum of 10 μM photosensitizer in 10% DMSO / H2O;

[0035] Fig.11 (a) Fluorescence emission spectra of DCFH in solution at different illumination times after adding 2b+t; (b) Fluorescence emission spectra of DCFH in solution at different illumination times after adding 2b+2t; (c) Fluorescence emission spectra of DCFH in solution at different illumination times after adding 2b+3t; (d) Comparison of the fluorescence emission intensity of DCFH at 525nm over time.

[0036] Fig.12 (a) UV absorption spectra of DPBF in the solution at different illumination times after adding 2b+t; (b) UV absorption spectra of DPBF in the solution at different illumination times after adding 2b+2t; (c) UV absorption spectra of DPBF in the solution at different illumination times after adding 2b+3t; (d) comparison of the absorption intensity of DPBF at 410nm changing with illumination time.

[0037] Fig.13 pH-activated photosensitizer 1 H NMR spectra.

[0038] Fig.14 pH-activated photosensitizer 13 C NMR spectrum.

[0039] Fig.15 HRMS graph of pH-activated photosensitizer.

[0040] Fig.16 (a) pH-activated photosensitizer plus H + The fluorescence intensity changes of DCFH in the previous solution under different illumination times; (b) the fluorescence intensity changes of the pH-activated photosensitizer with H + The fluorescence intensity changes of DCFH in the solution after adding H + Comparison of the fluorescence emission intensity of DCFH at 525 nm in the solution before and after changing with time; the numbers in Figures a and b are pH values.

[0041] Fig.17 pH-activated photosensitizers at different pH + Fluorescence emission spectra at . DETAILED DESCRIPTION

[0042] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in each embodiment of the present invention described below can be combined with each other as long as they do not conflict with each other.

[0043] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.

[0044] Example 1: Synthesis and characterization of photosensitizer

[0045] 1. Synthesis of photosensitizer

[0046] The synthetic reaction formula of the photosensitizer is as follows:

[0047]

[0048] (1) Synthesis of compound 2b+t:

[0049] Compound 2b (199.9 mg, 0.42 mmol) was added to a 100 mL round-bottom flask, dissolved with 10 mL acetic acid, and then thiophene aldehyde (58 mg, 0.52 mmol) was added to the round-bottom flask, and then the resulting reaction mixture was heated at 110°C for 12 h. After the reaction was completed, the mixture was cooled and concentrated under reduced pressure, and then the obtained product was purified by column chromatography (dichloromethane: methanol = 400: 1-100; 5 v / v) to obtain the purple target product (yield 156 mg, yield 65.16%). The NMR and mass spectrometry information of the product are as follows:

[0050] 1H NMR(600MHz,Chloroform-d)δ7.96(d,J=7.7Hz,1H),7.63(td,J=7.5,1.1Hz,1H),7.57-7.52(m,2H),7.37(d,J=5.1H z,1H),7.24-7.19(m,2H),7.10(dd,J=5.1,3.6Hz,1H),6.49(d,J=8.9Hz,1H),6.44(d,J=2.5Hz,1H),6.35(dd,J=8.9 ,2.6Hz,1H),3.37(q,J=7.1Hz,4H),2.92(dddd,J=15.7,6.7,4.7,1.6Hz,1H),2.69(dddd,J=15.9,9.0,4.9,2.0Hz,1 H),2.04(ddd,J=16.0,6.3,4.7Hz,1H),1.77-1.69(m,2H),1.63(ddd,J=16.0,8.4,4.7Hz,1H),1.18(t,J=7.0Hz,6H). 13 C NMR (151MHz, CDCl3) δ170.22,152.58,152.43,149.54,147.18,140.71,134.58,129.38,129.10,128.71,128.18,127.83 ,127.33,126.60,125.12,123.66,118.39,108.96,108.25,105.04,97.48,44.57,27.64,23.03,22.11,12.73.ESI-MS(M) + [m / z] 470.17844, calculated as 470.17844, M = C 29 H 28 NO3S + .

[0051] (2) Synthesis of compound 2b+2t:

[0052] Compound 2b (463 mg, 0.97 mmol) was added to a 100 mL round-bottom flask, dissolved with 20 mL acetic acid, and then 2,2-bithiophene-5-acetaldehyde (376 mg, 1.94 mmol) was added to the round-bottom flask, and then the resulting reaction mixture was refluxed at 110°C overnight. After the reaction was completed, the mixture was cooled and concentrated under reduced pressure, and then the resulting product was purified by column chromatography (dichloromethane: methanol = 200: 1-100: 7 v / v) to obtain a blue target product (yield 318 mg, yield 50.27%). The NMR and mass spectrometry information of the product are as follows:

[0053] 1 H NMR(600MHz,Chloroform-d)δ8.01(d,J=7.7Hz,1H),7.65-7.60(m,2H),7.58-7.53(m,1H), 7.25-7.21(m,3H),7.20-7.16(m,2H),7.03(dd,J=5.1,3.6Hz,1H),6.57(d,J=8.9Hz,1H),6 .54(d,J=2.4Hz,1H),6.43(dd,J=9.1,2.5Hz,1H),3.41(q,J=7.1Hz,4H),2.91(d,J=16.3Hz ,1H),2.73(t,J=12.4Hz,1H),2.15-2.09(m,1H),1.82-1.72(m,3H),1.20(t,J=7.1Hz,6H). 13 C NMR (151MHz, CDCl3) δ169.84,139.47,137.38,134.17,131.47,129.49,128.98,128.16,127.44 ,126.24,125.03,124.40,124.10,124.04,97.28,44.85,27.69,23.50,21.91,12.75.ESI-MS(M) + [m / z] 552.16632, calculated as 552.16616, M = C 33 H 30 NO3S2 + .

[0054] (3) Synthesis of Compound 2b+3t

[0055] Compound 2b (457 mg, 0.96 mmol) was added to a 100 mL round-bottom flask and dissolved with 20 mL of acetic acid. Then, 2,2':5',2"-terthiophene-5-carboxaldehyde (582 mg, 2.11 mmol) was added to the round-bottom flask, and the resulting reaction mixture was refluxed at 110°C overnight. After the reaction was completed, the mixture was cooled and concentrated under reduced pressure, and the resulting product was purified by column chromatography (dichloromethane: methanol = 200: 1-100; 11 v / v) to obtain a green target product (yield 387 mg, yield 54.90%). The NMR and mass spectrometry information of the product are as follows:

[0056] 1H NMR(600MHz,Chloroform-d)δ7.99(d,J=7.7Hz,1H),7.63(t,J=7.4Hz,1H),7.57-7.52(m,2H),7.24-7.22( m,1H),7.18(td,J=8.6,4.3Hz,4H),7.12(d,J=3.8Hz,1H),7.09(d,J=3.8Hz,1H),7.02(dd,J=5.1,3.6Hz,1H ),6.53(d,J=8.9Hz,1H),6.49(d,J=2.5Hz,1H),6.39(dd,J=8.9,2.6Hz,1H),3.39(q,J=7.1Hz,4H),2.91(d ,J=16.3Hz,1H),2.75-2.67(m,1H),2.08(dd,J=14.6,6.5Hz,1H),1.74-1.67(m,3H),1.19(t,J=7.1Hz,6H). 13 C NMR (151MHz, CDCl3) δ129.44,128.85,128.09,124.78,124.64,124.51,123.95,44.71,27.75,23.29,22.00,12.75.ESI-MS(M) + [m / z] 634.15388, calculated result is 634.15388, M = C 37 H 32 NO3S3 + .

[0057] 2. Characterization of photosensitizers

[0058] (1) Test method

[0059] 1) Nuclear magnetic resonance test: The compound was dissolved in deuterated chloroform (CDCl3) at room temperature using an AVANCE III nuclear magnetic resonance instrument produced by Bruker, Germany, and the frequency was set to 400 / 600 MHz to determine the structure of the compound.

[0060] 2) Mass spectrometry: A Q Exactive HF-X liquid chromatography-mass spectrometer produced by Thermo Fisher Scientific was used to determine the molecular weight of the target product.

[0061] 3) Fluorescence emission spectrum test: The FLS980 steady-state fluorescence spectrometer produced in Edinburgh, UK, was used to measure the fluorescence emission intensity of the target product under different experimental conditions, draw fluorescence emission spectra under different conditions, and analyze these spectra to obtain the fluorescence characteristics of each compound. Among them, the sensitivity is the water Raman peak signal-to-noise ratio> 12000:1, and the transient wavelength range is 300-1700nm.

[0062] 4) UV absorption spectrum test: Using the UV-2700i UV-visible spectrophotometer produced by Shimadzu Corporation of Japan, the UV absorption intensity of the target product under different experimental conditions was experimentally determined, and the UV absorption spectra under different conditions were plotted. These spectra were analyzed to obtain the generation of singlet oxygen in each compound. Quartz cuvettes (width = 1 cm) were used for all spectrophotometric and fluorescence measurements.

[0063] (2) Test results

[0064] 1) 1 H NMR, 13 C NMR and mass spectrometry characterization: The prepared compounds 2b+t, 2b+2t and 2b+3t were dissolved in deuterated chloroform and 1 H NMR ( Figure 1-3 ), 13 C NMR ( Figure 4-6 ) and mass spectrometry ( Figure 7-9 ) proved the structures of 2b+t, 2b+2t and 2b+3t.

[0065] 2) Spectroscopic determination: By measuring the photophysical properties of the three photosensitizers in solution, we can know ( Fig.10 ), with the increase of the amount of thiophene in the compound, the absorption wavelength of the photosensitizer has red shifted. Among them, the maximum absorption wavelength of 2b+t is 575nm, the maximum absorption wavelength of 2b+2t is 610nm, and the maximum absorption wavelength of 2b+3t is 632nm.

[0066] 3) Detection of reactive oxygen species: The compound 2'-7'-dichlorodihydrofluorescein (DCFH) is used as an indicator for detecting reactive oxygen species in the solution. When reactive oxygen species are generated in the system, the non-fluorescent DCFH will be oxidized and emit obvious fluorescence at 525nm. 10μM 2b+t, 2b+2t and 2b+3t were dissolved in 5mL DMSO / PBS = 1:9 (v / v) containing 5μM DCFH. The mixture was then placed in a test tube and irradiated with 3mW·cm -2 The samples were irradiated with LED light (400-800 nm), and the fluorescence intensity changes of the samples at 525 nm were recorded using a fluorescence spectrometer.

[0067] Through Fig.11 (a)(b)(c) shows that as the illumination time increases, the fluorescence emission intensity of the three photosensitizers at 525nm increases and then gradually stabilizes. This phenomenon indicates that active oxygen is generated in these three photosensitizers. Fig.11(d) Analysis shows that the amount of active oxygen produced by these three photosensitizers as the illumination time increases is as follows: 2b+2t>2b+3t>2b+t.

[0068] 4) Singlet oxygen test: The compound 1,3-diphenylisobenzofuran (DPBF) was used as an indicator to detect the amount of singlet oxygen produced in the solution. When singlet oxygen is produced in the solution, DPBF will be oxidized by the singlet oxygen, resulting in a decrease in the absorbance of the solution at 410nm. 10μM 2b+t, 2b+2t and 2b+3t were dissolved in 5mL DMSO / PBS=1:9 (v / v) containing 25μM DPBF. The mixture was then placed in a test tube and irradiated with 3mW·cm -2 The samples were irradiated with LED light (400-800 nm) and the absorption changes of the samples at 410 nm were recorded using a UV-visible spectrophotometer.

[0069] Through Fig.12 (a)(b)(c) shows that as the illumination time increases, the ultraviolet absorption intensity of the three photosensitizers at 410nm decreases and eventually stabilizes. This phenomenon indicates that the three photosensitizers produce a large amount of singlet oxygen after illumination. Fig.12 (d) Analysis shows that as the illumination time increases, the amount of singlet oxygen produced by these three photosensitizers decreases in the order of: 2b+3t>2b+t>2b+2t.

[0070] 5) Theoretical calculation: In order to explore the relationship between the photophysical properties and structure of the photosensitizer, density functional theory was used, using the B3LYP method and the 6-31G basis set to calculate the three photosensitizers. The HOMO-LUMO orbital energy levels and orbital compositions of the frontier molecular orbitals are shown in Tables 1 and 2.

[0071] According to the data of HOMO and LOMO in Table 1, the HOMO-LUMO energy gap of 2b+t in the three compounds is 2.447eV, the HOMO-LUMO energy gap of 2b+2t is 2.175eV, and the HOMO-LUMO energy gap of 2b+3t is 1.981eV. Among them, the energy gap value of 2b+t is the largest, and the energy gap value of 2b+3t is the smallest, indicating that the energy required for the electronic transition of the molecules of the 2b+t compound is higher, and the energy required for the electronic transition of the molecules of the 2b+3t compound is lower, it is easier to be excited, and the excitation wavelength is longer.

[0072] Table 1 Energy level values ​​of HOMO-LUMO orbitals of three photosensitizers

[0073]

[0074] Table 2 HOMO-LUMO orbitals of three photosensitizers

[0075]

[0076]

[0077] Example 2: Synthesis and characterization of pH-activated photosensitizers

[0078] 1. Synthesis of pH-activated photosensitizer

[0079] The synthetic reaction formula of pH activated photosensitizer is as follows:

[0080]

[0081] The specific synthesis method is as follows: Compound 2b+3t (55 mg, 0.075 mmol) is added to a 100 mL round-bottom flask, dissolved with 20 mL of dichloromethane, and then NHS (11.85 mg, 0.103 mmol) and EDC (14.4 mg, 0.075 mmol) are added to the round-bottom flask in a dark environment, and then refluxed and stirred at 40°C for 5 h. After stirring, adamantine (36 mg, 0.238 mmol) and three drops of triethylamine are added to the round-bottom flask, and refluxed and stirred at 40°C overnight. After the reaction, the obtained reactant is concentrated under reduced pressure using a rotary evaporator, and the product is purified by column chromatography (dichloromethane: ethanol = 100: 1-100: 5) to obtain a yellow solid target product, a pH-activated photosensitizer (yield 14.7 mg, yield 67.88%). The NMR and mass spectrometry information of the product are as follows:

[0082] 1H NMR(400MHz,Chloroform-d)δ7.69(dd,J=6.7,1.6Hz,1H),7.36(d,J=2.1Hz,1H),7.35-7.25(m,2H),7.15(dd,J=5.1,1.1Hz,1H),7.10(dd,J=5.8,3 .9Hz,2H),7.06(d,J=3.9Hz,1H),7.03(q,J=3.8Hz,2H),6.97-6.95(m,1H ),6.93(dd,J=7.5,1.9Hz,1H),6.44(d,J=8.8Hz,1H),6.31(d,J=2.5Hz,1H ),6.21(dd,J=8.9,2.6Hz,1H),3.29(q,J=7.1Hz,4H),2.86(dt,J=16.0,5 .6Hz,1H),2.70-2.60(m,1H),2.32(d,J=11.8Hz,3H),2.14(d,J=11.8Hz,3 H),2.05(ddd,J=16.1,6.5,4.4Hz,1H),1.96-1.89(m,3H),1.67(ddt,J=18 .1,10.0,5.0Hz,3H),1.53(q,J=13.9,13.1Hz,6H),1.12(t,J=7.0Hz,6H). 13 C NMR (101MHz, CDCl3) δ169.67,152.52,151.25,148.72,144.44,140.16,137.74,137.21,136.4 4,136.32,132.15,131.51,129.76,128.66,128.51,128.02,127.94,124.66,124.57,124.39,1 24.20,124.10,123.83,123.81,123.74,122.56,122.36,116.84,113.03,108.26,107.89,98. 17,67.47,59.35,53.53,44.38,39.30,36.59,30.08,28.24,23.34,22.38,12.75.ESI-MS(M+H) + [m / z] 767.27972, calculated as 767.27997, M = C 47 H 46 N2O2S3.

[0083] 2. Characterization of pH-activated photosensitizers:

[0084] 1) 1 H NMR,13 C NMR and mass spectrometry characterization: The new compound pH-activated photosensitizer was obtained by modifying the 2b+3T structure and purifying it. This activated photosensitizer was dissolved in deuterated chloroform and 1 H NMR ( Fig.13 ), 13 CNMR( Fig.14 ) and mass spectrometry ( Fig.15 ) detection, proving the structure of the pH-activated photosensitizer.

[0085] 2) Reactive oxygen test before and after the addition of pH-activated photosensitizer to the marker: Measure the reactive oxygen species at different illumination times (min) before and after the addition of pH-activated photosensitizer to the marker, such as Fig.16 As shown in the figure, it can be seen that the fluorescence of the activated photosensitizer is significantly enhanced after the addition of the marker, indicating that the activated photosensitizer can be successfully activated to generate a large amount of reactive oxygen.

[0086] 3) NIR-II spectrum of pH-activated photosensitizers: The fluorescence emission spectrum of the NIR-II region of the activated photosensitizers was investigated, such as Fig.17 As shown. Fig.17 Analysis shows that this activated photosensitizer is activated by H + As the content of α-hydroxy-1-nitropropene increases, the fluorescence emission intensity in the NIR-Ⅱ region continues to increase. This shows that this activated photosensitizer has good fluorescence imaging potential.

[0087] In summary, the present invention synthesized three photosensitizers by modifying rhodamine derivatives and controlling the number of thiophenes connected thereto. According to the heavy atom effect, the presence of sulfur atoms in these three photosensitizers enhances spin-orbit coupling, thereby promoting intersystem crossing and generating more reactive oxygen. Experiments have found that the photosensitizer 2b+3t, which contains the most thiophenes, produces the most singlet oxygen. This work provides a new idea for constructing photosensitizers that do not contain heavy metals.

[0088] At the same time, the present invention constructs a pH-activated photosensitizer by modifying the photosensitizer 2b+3t. This activated photosensitizer retains the characteristics of rhodamine dyes. After being specifically activated by tumor markers, it can produce a large amount of singlet oxygen through ring opening, and has the advantages of strong stability, easy synthesis, high biocompatibility, etc. Experiments have found that this activated photosensitizer can produce strong fluorescence emission in the NIR-Ⅱ region, which can be used for NIR-Ⅱ in vivo imaging of cancerous sites. This work provides a new strategy for the integration of diagnosis and treatment of cancer treatment, and has broad development prospects.

[0089] The embodiments of the present invention are described in detail above, but the present invention is not limited to the described embodiments. For those skilled in the art, various changes, modifications, substitutions and variations of these embodiments are made without departing from the principles and spirit of the present invention, and still fall within the protection scope of the present invention.

Claims

1. A pH-activated photosensitizer, characterized in that: The structural formula of the pH activated photosensitizer is shown below:

2. The method for preparing the pH activated photosensitizer according to claim 1, characterized in that: According to the following reaction formula, the preparation method comprises the following steps: S1, dissolving compound 2b in acetic acid, adding 2,2':5',2"-terthiophene-5-carboxaldehyde, and then reflux at 100°C-120°C for 8-15 hours. After the reaction, cooling under reduced pressure, concentrating, and purifying by column chromatography to obtain compound 2b+3t; S2. Dissolve compound 2b+3t in dichloromethane, add NHS and EDC, reflux with stirring at 35°C-50°C for 4-7 hours, then add adamantine and triethylamine, continue to reflux with stirring at 35°C-50°C for 8-15 hours, and after the reaction, concentrate under reduced pressure and purify by column chromatography to obtain a pH-activated photosensitizer.

3. The method for preparing the pH activated photosensitizer according to claim 2, characterized in that: In S1, the molar ratio of the compound 2b to 2,2':5',2"-terthiophene-5-carboxaldehyde is 0.8-1.0:2.0-3.

0.

4. The method for preparing the pH activated photosensitizer according to claim 2, characterized in that: The column chromatography purification in S1 uses dichloromethane:methanol=200:1-100; v / v as the elution solvent.

5. The method for preparing the pH activated photosensitizer according to claim 2, characterized in that: In S2, the molar ratio of the compound 2b+3t, NHS, EDC and adamantine is 0.06-0.09: 0.1-0.2: 0.06-0.09: 0.2-0.

3.

6. The method for preparing the pH activated photosensitizer according to claim 2, characterized in that: In S2, the concentration of the compound 2b+3t in dichloromethane is 40-60 mg / 20 mL.

7. The method for preparing the pH activated photosensitizer according to claim 2, characterized in that: In S2, NHS and EDC were added under light-protected conditions.

8. The method for preparing the pH activated photosensitizer according to claim 2, characterized in that: The column chromatography purification in S2 uses dichloromethane:ethanol=100:1-100:v / v as the elution solvent.

9. Use of the pH-activated photosensitizer according to claim 1 in the preparation of an integrated tumor diagnosis and treatment preparation.

Citation Information

Patent Citations

  • Rhodamine-containing lactam group micromolecule pH fluorescent probe and synthetic method

    CN104017569A

  • Fluorescent probe for detecting acetylcholin esterase as well as preparation method and application of fluorescent probe

    CN115215769A

  • Small molecule pyroptosis inducer and application thereof as tumor sonodynamic therapeutic agent

    CN117603197A

  • Near-infrared fluorescent probe, preparation method thereof and application of near-infrared fluorescent probe in dual-response detection of Cu &lt; 2 + &gt; and A &lt; beta &gt; aggregate

    CN117800982A